Proteostasis Therapeutics, Inc. is a United States-based biopharmaceutical company developing small molecule therapeutics to treat diseases caused by defects in protein processing. The Company identifies selective drug candidates that modulate the proteostasis imbalance in the cell by combining the Disease-Relevant Translation, DRT platform, which is a phenotypic screening approach based on the use of functionally pertinent cellular assays and disease relevant models. It is focused on developing a triple combination therapy for cystic fibrosis. It is focused on researching therapeutic strategies for modulating the unfolded protein response. It is focused on researching Usp14 inhibitors to manage the clearance of aggregation-prone proteins, such as tau in Alzheimer's disease and others. The Proteostasis Network consists of over 1,000 proteins organized into pathways. Its DRT platform combines genomics, proteomics and functional assays with medicinal chemistry and systems biology.